Byterna Therapeutics

Byterna Therapeutics is a biotechnology company pioneering the development of circular RNA (circRNA) therapeutics to treat a broad range of diseases. By utilizing the inherent stability and long-lasting expression of circRNA, the company aims to address the limitations of traditional linear mRNA therapies, such as short half-life and transient protein production. Byterna's platform is designed to enable potent and durable protein expression, potentially reducing dosing frequency and improving patient outcomes. The company is currently advancing a diverse pipeline of programs in the pre-clinical stage, focusing on areas such as protein replacement and vaccines. Headquartered in New York City, Byterna is backed by leading life science investors and led by experts in RNA biology.